A ‘conflict of interest-free’ FDA advisory committee policy is a terrible idea

What's new in pharma

March 14, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Nick Wass/AP Opinion: A 'conflict of interest-free' FDA advisory committee policy is a terrible idea Qualified experts who have also been actively involved in relevant and innovative scientific work are critical to FDA advisory committees. By Peter J. Pitts Study reveals how often medical device makers report safety incidents late to FDA In this edition of STAT's Health Tech newsletter: New study finds medical device makers are late in filing safety incident reports, and more By Mario Aguilar Opinion: Vaccine hesitancy is about much more than misinformation We analyzed 50 million vaccine-related social media posts and found that concern emerges from an interplay of interconnected social and economic factors. By Huseyin Zeyd Koytak Alex Hogan/STAT STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser